Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer
开发下一代治疗前列腺癌的 FABP5 抑制剂
基本信息
- 批准号:10092979
- 负责人:
- 金额:$ 67.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-01 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AcidsAffinityAlgorithm DesignAmes AssayAndrogen AntagonistsBindingBiologicalBiological AssayCancer BiologyCancer EtiologyCastrationCellsCessation of lifeClinicalComputer AssistedCytochrome P450DataDevelopmentDiseaseDockingDrug DesignDrug KineticsEnzymesFDA approvedFree EnergyGenerationsGenetic TranscriptionGenetically Engineered MouseGoalsHalf-LifeHeartIn VitroInjectionsInterventionIon ChannelLeadLinkLipidsMYC geneMalignant neoplasm of prostateMapsMetabolismMetastatic Prostate CancerMetastatic toMolecularMusNeoplasm MetastasisNuclear ReceptorsNude MiceOutcomePatientsPharmaceutical ChemistryPlasmaPositioning AttributePreclinical TestingProductionProstateProstate Cancer therapyProstaticProtein IsoformsProteinsReceptor SignalingResistanceSignal TransductionStructureSystemTechniquesTestingTherapeuticTherapeutic InterventionTimeTranslationsUnited Statesadvanced prostate canceranalogandrogen sensitivebasecastration resistant prostate cancerchemical synthesiscytotoxicitydesignefficacy testingfatty acid metabolismfatty acid-binding proteinsimprovedin silicoin vivoin vivo evaluationinhibitor/antagonistintracellular protein transportlead optimizationlipid transportmenmolecular dynamicsmouse modelmultidisciplinarynext generationnovelpre-clinicalprogramsprostate cancer cell lineprostate cancer metastasisprostate cancer modelreceptorscaffoldscreeningsubcutaneoustargeted treatmenttaxanetherapeutic developmenttumor growthtumorigenic
项目摘要
Project Summary
Despite advances in anti-androgen and taxane-based therapies, prostate cancer (PC) often becomes
castration-resistant, metastatic, and incurable. Consequently, there is an urgent need to develop novel
interventions to treat metastatic PC. Lipid signaling and metabolism are major drivers of PC metastasis and
present ideal targets for therapeutic intervention. However, therapeutic exploitation of lipid signaling systems is
hampered by the existence of multiple lipid metabolizing enzymes and nuclear receptors, which would
necessitate targeting these systems in parallel. Fatty acid binding protein 5 (FABP5) is an intracellular carrier
that shuttles bioactive lipids to nuclear receptors, thereby activating gene transcription programs that enhance
tumor growth and metastasis. FABP5 is not expressed in the normal prostate but becomes highly upregulated
in advanced metastatic PC. Our group has obtained preliminary data demonstrating that FABP5 is
indispensable for the delivery of pro-tumorigenic lipids produced by multiple cytosolic to nuclear receptors to
promote PC metastasis. This positions FABP5 as an essential node in a PC lipid signaling network and an
attractive target for the development of therapeutics to treat metastatic PC. Despite the considerable promise
of FABP5 inhibitors as potential PC therapeutics, potent and selective inhibitors have yet to emerge. The major
goal of this proposal is to develop and optimize novel potent and selective FABP5 inhibitors. The proposed
multidisciplinary project will be carried out by a highly qualified team with expertise in computer-aided drug
design, medicinal chemistry, and PC biology. Aim 1 will leverage structure-based drug design and iterative
chemical synthesis approaches to identify and optimize FABP5 inhibitors for potency and selectivity. Aim 2 will
employ a robust in vitro inhibitor testing platform including assessments of inhibitor potency, efficacy,
selectivity, stability, and cytotoxicity in PC cell-lines and non-transformed cells. Aim 3 will assess the efficacy of
candidate inhibitors in mouse models of PC, including a novel genetically engineered mouse model of
androgen-dependent and castration-resistant PC. We will also assess the efficacy of FABP5 inhibitors when
used as monotherapies and in combination with FDA approved therapeutics. Successful completion of the
proposed studies will lead to the development of optimized FABP5 inhibitor scaffolds that can be advanced to
late stage IND-enabling studies and eventual clinical deployment.
项目摘要
尽管抗雄激素和紫杉烷类药物治疗取得了进展,但前列腺癌(PC)往往成为
去势抵抗性转移性无法治愈因此,迫切需要发展小说
治疗转移性PC。脂质信号传导和代谢是PC转移的主要驱动力,
为治疗干预提供了理想的靶点。然而,脂质信号传导系统的治疗性开发是不可能的。
由于存在多种脂质代谢酶和核受体,
必须同时瞄准这些系统。脂肪酸结合蛋白5(FABP5)是一种细胞内载体
将生物活性脂质运送到核受体,从而激活基因转录程序,
肿瘤生长和转移。FABP5在正常前列腺中不表达,但高度上调
晚期转移性PC我们的小组已经获得了初步数据,表明FABP5是
对于将由多种胞质到核受体产生的促肿瘤发生脂质递送到
促进PC转移。这将FABP5定位为PC脂质信号传导网络中的重要节点,并将其定位为一个重要的信号传导通路。
对于治疗转移性PC的治疗剂的开发是有吸引力的靶点。尽管有相当大的希望
FABP5抑制剂作为潜在的PC治疗剂,有效的和选择性的抑制剂尚未出现。主要
该提案的目的是开发和优化新的有效的和选择性的FABP5抑制剂。拟议
一个多学科项目将由一个具有计算机辅助药物方面专门知识的高素质小组执行
设计、药物化学和PC生物学。目标1将利用基于结构的药物设计和迭代
化学合成方法来鉴定和优化FABP5抑制剂的效力和选择性。目标2将
采用稳健的体外抑制剂测试平台,包括评估抑制剂效力,功效,
在PC细胞系和非转化细胞中的选择性、稳定性和细胞毒性。目标3将评估
候选抑制剂的小鼠模型的PC,包括一种新的基因工程小鼠模型,
雄激素依赖和去势抵抗PC。我们还将评估FABP5抑制剂的疗效,
用作单一疗法并与FDA批准的疗法组合。成功完成
拟议的研究将导致开发优化的FABP5抑制剂支架,
后期IND使能研究和最终临床部署。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Martin Kaczocha其他文献
Martin Kaczocha的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Martin Kaczocha', 18)}}的其他基金
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer
开发下一代治疗前列腺癌的 FABP5 抑制剂
- 批准号:
10333221 - 财政年份:2020
- 资助金额:
$ 67.67万 - 项目类别:
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer
开发下一代治疗前列腺癌的 FABP5 抑制剂
- 批准号:
10548832 - 财政年份:2020
- 资助金额:
$ 67.67万 - 项目类别:
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer
开发下一代治疗前列腺癌的 FABP5 抑制剂
- 批准号:
9887053 - 财政年份:2020
- 资助金额:
$ 67.67万 - 项目类别:
FABPs: Novel Roles in Pain and Inflammation
FABP:在疼痛和炎症中的新作用
- 批准号:
10403597 - 财政年份:2014
- 资助金额:
$ 67.67万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 67.67万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 67.67万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 67.67万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 67.67万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 67.67万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 67.67万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 67.67万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 67.67万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 67.67万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 67.67万 - 项目类别:
Continuing Grant